The Leishmania pifanoi amastigote
antigen P-8 has been previously shown to induce protective immunity in a murine model of
cutaneous leishmaniasis (L. Soong, S. M. Duboise, P. Kima, and D. McMahon-Pratt, Infect. Immun. 63:3559-3566, 1995). As this
antigen is of interest for further
vaccine studies, the biochemical characterization of P-8 was undertaken.
Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, Western-blot analysis, and gel filtration chromatography revealed that P-8
antigen consisted of two proteoglycolipid complexes. The P-8
epitope is associated with the L. pifanoi amastigote-specific
glycolipid components found in the two complexes. The P-8 complex 1 (P-8c1) consists of a 56-kDa
serine metalloproteinase,
apolipoprotein E (derived from
fetal bovine serum), and amastigote-specific
glycolipids. The P-8 complex 2 (P-8c2) consists of a 31-kDa
cysteine proteinase associated with amastigote
glycolipids. Biochemical analyses suggest that the P-8 antigenic
glycolipids may be distinct from previously described Leishmania
glycolipids (glycosylinositol-
phospholipids and
sphingoglycolipids). Protective immunity studies revealed that P-8c1 (
serine metalloproteinase-
glycolipid complex) confers comparable protection against
infection as immunopurified P-8. The isolated P-8c2 (
cysteine proteinase-
glycolipid complex) does not provide significant protection, nor does stimulation with P-8c2 result in significant T-cell activation in P-8- or P-8c2-vaccinated mice. Consequently, the P-8c1 complex appears to be the immunodominant component of P-8.